speb/financial-data huggingface dataset:
RNA income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 1000.00
RNA balance_sheet (annual, 2023-12-31) — Other Properties: 10034000.00
RNA balance_sheet (annual, 2023-12-31) — Payables: 498000.00
RNA balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 1153000.00
RNA balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 848000.00
RNA balance_sheet (annual, 2023-12-31) — Prepaid Assets: 105000.00
RNA income_statement (annual, 2023-12-31) — Pretax Income: -6385000.00
RNA balance_sheet (annual, 2023-12-31) — Properties: 0.00
RNA cash_flow (annual, 2023-12-31) — Purchase Of PPE: -320000.00
RNA balance_sheet (annual, 2023-12-31) — Receivables: 751000.00
RNA income_statement (annual, 2023-12-31) — Reconciled Depreciation: 138000.00
RNA income_statement (annual, 2023-12-31) — Research And Development: 12653000.00
RNA income_statement (annual, 2023-12-31) — Selling General And Administration: 3497000.00
RNA balance_sheet (annual, 2023-12-31) — Share Issued: 17105643.00
RNA cash_flow (annual, 2023-12-31) — Stock Based Compensation: 2507000.00
RNA balance_sheet (annual, 2023-12-31) — Stockholders Equity: -70619000.00
RNA balance_sheet (annual, 2023-12-31) — Tangible Book Value: -70619000.00
RNA income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
RNA income_statement (annual, 2023-12-31) — Tax Provision: 0.00
RNA income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
RNA balance_sheet (annual, 2023-12-31) — Total Assets: 10293000.00
RNA balance_sheet (annual, 2023-12-31) — Total Capitalization: -70619000.00
RNA balance_sheet (annual, 2023-12-31) — Total Debt: 9852000.00
RNA balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: -70619000.00
RNA income_statement (annual, 2023-12-31) — Total Expenses: 16150000.00
RNA balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 80912000.00
RNA balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 9437000.00
RNA balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 47111000.00
RNA income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -6386000.00
RNA balance_sheet (annual, 2023-12-31) — Working Capital: -32945000.00
RNA income_statement (annual, 2024-12-31) — +Operating Expense: 24115000.00
RNA income_statement (quarterly, 2024-12-31) — +Operating Expense: 47222000.00
RNA income_statement (annual, 2024-12-31) — +Total Revenue: 10897000.00
RNA income_statement (quarterly, 2024-12-31) — +Total Revenue: 2973000.00
RNA balance_sheet (annual, 2024-12-31) — Accounts Payable: 532000.00
RNA balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 532000.00
RNA balance_sheet (annual, 2024-12-31) — Accounts Receivable: 0.00
RNA balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 0.00
RNA balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -1234000.00
RNA balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -1234000.00
RNA income_statement (annual, 2024-12-31) — Basic Average Shares: 17114000.00
RNA income_statement (annual, 2024-12-31) — Basic EPS: -1.47
RNA cash_flow (annual, 2024-12-31) — Beginning Cash Position: 0.00
RNA cash_flow (quarterly, 2024-12-31) — Beginning Cash Position: 0.00
RNA cash_flow (annual, 2024-12-31) — Capital Expenditure: -266000.00
RNA cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -218000.00
RNA balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 6801000.00
RNA balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 6801000.00
RNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 22819000.00
RNA cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Financing Activities: 8481000.00
RNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -266000.00
RNA cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Investing Activities: -218000.00
RNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -22553000.00
RNA cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Operating Activities: -8263000.00
RNA cash_flow (annual, 2024-12-31) — Change In Account Payable: 34000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Account Payable: 212000.00
RNA cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -64000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Accrued Expense: 68000.00
RNA cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 0.00
RNA cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 574000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Other Current Liabilities: 252000.00
RNA cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -13807000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Other Working Capital: -3917000.00
RNA cash_flow (annual, 2024-12-31) — Change In Payable: 34000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Payable: 212000.00
RNA cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -30000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Payables And Accrued Expense: 280000.00
RNA cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -378000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Prepaid Assets: 68000.00
RNA cash_flow (annual, 2024-12-31) — Change In Receivables: 751000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Receivables: 0.00
RNA cash_flow (annual, 2024-12-31) — Change In Working Capital: -12890000.00
RNA cash_flow (quarterly, 2024-12-31) — Change In Working Capital: -3229000.00
RNA cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 751000.00
RNA cash_flow (quarterly, 2024-12-31) — Changes In Account Receivables: 0.00
RNA balance_sheet (annual, 2024-12-31) — Common Stock Equity: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: -61108000.00
RNA balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 1193000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Accrued Expenses: 1193000.00
RNA balance_sheet (annual, 2024-12-31) — Current Assets: 483000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Assets: 483000.00
RNA balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 3844000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 3844000.00
RNA balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 3844000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 3844000.00
RNA balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 20987000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Deferred Liabilities: 20987000.00
RNA balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 20987000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Deferred Revenue: 20987000.00
RNA balance_sheet (annual, 2024-12-31) — Current Liabilities: 26802000.00
RNA balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 26802000.00
RNA cash_flow (annual, 2024-12-31) — Deferred Income Tax: 11906000.00
RNA cash_flow (quarterly, 2024-12-31) — Deferred Income Tax: 5265000.00
RNA cash_flow (annual, 2024-12-31) — Deferred Tax: 11906000.00
RNA cash_flow (quarterly, 2024-12-31) — Deferred Tax: 5265000.00
RNA cash_flow (annual, 2024-12-31) — Depreciation: 172000.00
RNA cash_flow (quarterly, 2024-12-31) — Depreciation: 58000.00
RNA cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 172000.00
RNA cash_flow (quarterly, 2024-12-31) — Depreciation Amortization Depletion: 58000.00
RNA cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 172000.00
RNA cash_flow (quarterly, 2024-12-31) — Depreciation And Amortization: 58000.00
RNA income_statement (annual, 2024-12-31) — Diluted Average Shares: 17124000.00
RNA income_statement (annual, 2024-12-31) — Diluted EPS: -1.47
RNA income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: -46195000.00
RNA income_statement (annual, 2024-12-31) — EBIT: -13218000.00
RNA income_statement (quarterly, 2024-12-31) — EBIT: -44249000.00
RNA income_statement (annual, 2024-12-31) — EBITDA: -13046000.00
RNA income_statement (quarterly, 2024-12-31) — EBITDA: -44191000.00
RNA cash_flow (annual, 2024-12-31) — End Cash Position: 0.00
RNA cash_flow (quarterly, 2024-12-31) — End Cash Position: 0.00
RNA cash_flow (annual, 2024-12-31) — Financing Cash Flow: 22819000.00
RNA cash_flow (quarterly, 2024-12-31) — Financing Cash Flow: 8481000.00
RNA cash_flow (annual, 2024-12-31) — Free Cash Flow: -22819000.00
RNA cash_flow (quarterly, 2024-12-31) — Free Cash Flow: -8481000.00
RNA cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: 0.00
RNA income_statement (annual, 2024-12-31) — General And Administrative Expense: 4916000.00
RNA income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 25777000.00
RNA balance_sheet (annual, 2024-12-31) — Gross PPE: 7937000.00
RNA balance_sheet (quarterly, 2024-12-31) — Gross PPE: 7937000.00
RNA balance_sheet (annual, 2024-12-31) — Invested Capital: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Invested Capital: -61108000.00
RNA cash_flow (annual, 2024-12-31) — Investing Cash Flow: -266000.00
RNA cash_flow (quarterly, 2024-12-31) — Investing Cash Flow: -218000.00
RNA balance_sheet (annual, 2024-12-31) — Leases: 288000.00
RNA balance_sheet (quarterly, 2024-12-31) — Leases: 288000.00
RNA balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 2957000.00
RNA balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 2957000.00
RNA balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 2957000.00
RNA balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 2957000.00
RNA balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 0.00
RNA balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 0.00
RNA income_statement (annual, 2024-12-31) — Net Income: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Net Income: -46195000.00
RNA income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: -46195000.00
RNA income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: -46195000.00
RNA income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -46195000.00
RNA income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -46195000.00
RNA cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -25122000.00
RNA cash_flow (quarterly, 2024-12-31) — Net Income From Continuing Operations: -11512000.00
RNA income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: -46195000.00
RNA cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 22819000.00
RNA cash_flow (quarterly, 2024-12-31) — Net Other Financing Charges: 8481000.00
RNA balance_sheet (annual, 2024-12-31) — Net PPE: 6703000.00
RNA balance_sheet (quarterly, 2024-12-31) — Net PPE: 6703000.00
RNA cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -266000.00
RNA cash_flow (quarterly, 2024-12-31) — Net PPE Purchase And Sale: -218000.00
RNA balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: -61108000.00
RNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 37961000.00
RNA balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Liabilities: 37961000.00
RNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 37961000.00
RNA balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Revenue: 37961000.00
RNA income_statement (annual, 2024-12-31) — Normalized EBITDA: -13046000.00
RNA income_statement (quarterly, 2024-12-31) — Normalized EBITDA: -44191000.00
RNA income_statement (annual, 2024-12-31) — Normalized Income: -25122000.00
RNA income_statement (quarterly, 2024-12-31) — Normalized Income: -46195000.00
RNA cash_flow (annual, 2024-12-31) — Operating Cash Flow: -22553000.00
RNA cash_flow (quarterly, 2024-12-31) — Operating Cash Flow: -8263000.00
RNA cash_flow (annual, 2024-12-31) — Operating Gains Losses: 204000.00
RNA income_statement (annual, 2024-12-31) — Operating Income: -13218000.00
RNA income_statement (quarterly, 2024-12-31) — Operating Income: -44249000.00
RNA income_statement (annual, 2024-12-31) — Operating Revenue: 10897000.00
RNA income_statement (quarterly, 2024-12-31) — Operating Revenue: 2973000.00
RNA balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 17105643.00
RNA balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 17105643.00
RNA balance_sheet (annual, 2024-12-31) — Other Equity Interest: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: -61108000.00
RNA income_statement (annual, 2024-12-31) — Other Gand A: 4916000.00
RNA income_statement (quarterly, 2024-12-31) — Other Gand A: 25777000.00
RNA income_statement (annual, 2024-12-31) — Other Income Expense: 2000.00
RNA income_statement (quarterly, 2024-12-31) — Other Income Expense: 4000.00
RNA cash_flow (annual, 2024-12-31) — Other Non Cash Items: 204000.00
RNA balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 574000.00
RNA balance_sheet (quarterly, 2024-12-31) — Other Non Current Liabilities: 574000.00
RNA income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 2000.00
RNA income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 4000.00
RNA balance_sheet (annual, 2024-12-31) — Other Properties: 7649000.00
RNA balance_sheet (quarterly, 2024-12-31) — Other Properties: 7649000.00
RNA balance_sheet (annual, 2024-12-31) — Payables: 532000.00
RNA balance_sheet (quarterly, 2024-12-31) — Payables: 532000.00
RNA balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 1725000.00
RNA balance_sheet (quarterly, 2024-12-31) — Payables And Accrued Expenses: 1725000.00
RNA balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 246000.00
RNA balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 246000.00
RNA balance_sheet (annual, 2024-12-31) — Prepaid Assets: 483000.00
RNA balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 483000.00
RNA income_statement (annual, 2024-12-31) — Pretax Income: -13216000.00
RNA income_statement (quarterly, 2024-12-31) — Pretax Income: -44245000.00
RNA balance_sheet (annual, 2024-12-31) — Properties: 0.00
RNA balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
RNA cash_flow (annual, 2024-12-31) — Purchase Of PPE: -266000.00
RNA cash_flow (quarterly, 2024-12-31) — Purchase Of PPE: -218000.00
RNA balance_sheet (annual, 2024-12-31) — Receivables: 0.00
RNA balance_sheet (quarterly, 2024-12-31) — Receivables: 0.00
RNA income_statement (annual, 2024-12-31) — Reconciled Depreciation: 172000.00
RNA income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 58000.00
RNA income_statement (annual, 2024-12-31) — Research And Development: 19199000.00
RNA income_statement (quarterly, 2024-12-31) — Research And Development: 21445000.00
RNA income_statement (annual, 2024-12-31) — Selling General And Administration: 4916000.00
RNA income_statement (quarterly, 2024-12-31) — Selling General And Administration: 25777000.00
RNA balance_sheet (annual, 2024-12-31) — Share Issued: 17105643.00
RNA balance_sheet (quarterly, 2024-12-31) — Share Issued: 17105643.00
RNA cash_flow (annual, 2024-12-31) — Stock Based Compensation: 3177000.00
RNA cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: 1090000.00
RNA balance_sheet (annual, 2024-12-31) — Stockholders Equity: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: -61108000.00
RNA balance_sheet (annual, 2024-12-31) — Tangible Book Value: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: -61108000.00
RNA income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
RNA income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
RNA income_statement (annual, 2024-12-31) — Tax Provision: 11906000.00
RNA income_statement (quarterly, 2024-12-31) — Tax Provision: 1950000.00
RNA income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
RNA income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.21
RNA balance_sheet (annual, 2024-12-31) — Total Assets: 7186000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Assets: 7186000.00
RNA balance_sheet (annual, 2024-12-31) — Total Capitalization: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Capitalization: -61108000.00
RNA balance_sheet (annual, 2024-12-31) — Total Debt: 6801000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Debt: 6801000.00
RNA balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: -61108000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: -61108000.00
RNA income_statement (annual, 2024-12-31) — Total Expenses: 24115000.00
RNA income_statement (quarterly, 2024-12-31) — Total Expenses: 47222000.00
RNA balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 68294000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 68294000.00
RNA balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 6703000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 6703000.00
RNA balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 41492000.00
RNA balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 41492000.00
RNA income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -13218000.00
RNA income_statement (quarterly, 2024-12-31) — Total Operating Income As Reported: -44249000.00
RNA balance_sheet (annual, 2024-12-31) — Working Capital: -26319000.00
RNA balance_sheet (quarterly, 2024-12-31) — Working Capital: -26319000.00
RNA income_statement (quarterly, 2025-03-31) — +Operating Expense: 9025000.00
RNA income_statement (quarterly, 2025-03-31) — +Total Revenue: 1573000.00
RNA income_statement (quarterly, 2025-03-31) — Basic Average Shares: 17084000.00
RNA income_statement (quarterly, 2025-03-31) — Basic EPS: -0.44
RNA cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 0.00
RNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 11103000.00
RNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 0.00
RNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -11103000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 37000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: 1247000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: -2223000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -574000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -2532000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Payable: 37000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 1284000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -928000.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Receivables: 0.00
RNA cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -4973000.00
RNA cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 0.00
RNA cash_flow (quarterly, 2025-03-31) — Depreciation: 53000.00
RNA cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 53000.00
RNA cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 53000.00
RNA income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 17124000.00
RNA income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.44
RNA income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -7449000.00
RNA income_statement (quarterly, 2025-03-31) — EBIT: -7452000.00
RNA income_statement (quarterly, 2025-03-31) — EBITDA: -7399000.00
RNA cash_flow (quarterly, 2025-03-31) — End Cash Position: 0.00
RNA cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 11103000.00
RNA cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -11103000.00
RNA income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 2088000.00
RNA cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 0.00
RNA income_statement (quarterly, 2025-03-31) — Net Income: -7449000.00
RNA income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -7449000.00
RNA income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -7449000.00
RNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -7449000.00
RNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -7449000.00
RNA cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -7449000.00
RNA income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -7449000.00
RNA cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: 11103000.00
RNA cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: 0.00
RNA income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -7399000.00
RNA income_statement (quarterly, 2025-03-31) — Normalized Income: -7449000.00
RNA cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -11103000.00
RNA income_statement (quarterly, 2025-03-31) — Operating Income: -7452000.00
RNA income_statement (quarterly, 2025-03-31) — Operating Revenue: 1573000.00
RNA income_statement (quarterly, 2025-03-31) — Other Gand A: 2088000.00
RNA income_statement (quarterly, 2025-03-31) — Other Income Expense: 3000.00
RNA cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 56000.00
RNA income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 3000.00
RNA income_statement (quarterly, 2025-03-31) — Pretax Income: -7449000.00
RNA cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: 0.00
RNA income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 53000.00
RNA income_statement (quarterly, 2025-03-31) — Research And Development: 6937000.00
RNA income_statement (quarterly, 2025-03-31) — Selling General And Administration: 2088000.00
RNA cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 1210000.00
RNA income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
RNA income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
RNA income_statement (quarterly, 2025-03-31) — Total Expenses: 9025000.00
RNA income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -7452000.00
RNA balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 451000.00
RNA balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -1403000.00
RNA balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 212836000.00
RNA balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 4279000.00
RNA balance_sheet (quarterly, 2025-09-30) — Capital Stock: 17000.00
RNA balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 270000000.00
RNA balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 270000000.00
RNA balance_sheet (quarterly, 2025-09-30) — Common Stock: 17000.00
RNA balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 5605000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Assets: 271262000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 3967000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 3967000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 19123000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 19123000.00
RNA balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 31739000.00
RNA balance_sheet (quarterly, 2025-09-30) — Gross PPE: 7685000.00
RNA balance_sheet (quarterly, 2025-09-30) — Invested Capital: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Leases: 0.00
RNA balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 312000.00
RNA balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 312000.00
RNA balance_sheet (quarterly, 2025-09-30) — Net PPE: 6282000.00
RNA balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 32066000.00
RNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 32066000.00
RNA balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 17105643.00
RNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 574000.00
RNA balance_sheet (quarterly, 2025-09-30) — Other Properties: 7685000.00
RNA balance_sheet (quarterly, 2025-09-30) — Payables: 451000.00
RNA balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 6056000.00
RNA balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 2593000.00
RNA balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 1262000.00
RNA balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
RNA balance_sheet (quarterly, 2025-09-30) — Share Issued: 17105643.00
RNA balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Assets: 277544000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Debt: 4279000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 212853000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 64691000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 6282000.00
RNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 32952000.00
RNA balance_sheet (quarterly, 2025-09-30) — Working Capital: 239523000.00
RNA income_statement (annual, 2025-12-31) — +Operating Expense: 95432000.00
RNA income_statement (quarterly, 2025-12-31) — +Operating Expense: 48894000.00
RNA income_statement (annual, 2025-12-31) — +Total Revenue: 18618000.00
RNA income_statement (quarterly, 2025-12-31) — +Total Revenue: 859000.00
RNA balance_sheet (annual, 2025-12-31) — Accounts Payable: 4398000.00
RNA balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 4398000.00
RNA balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -2844000.00
RNA balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -2844000.00
RNA balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 207270000.00
RNA balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 207270000.00
RNA income_statement (annual, 2025-12-31) — Basic Average Shares: 17105643.00
RNA income_statement (annual, 2025-12-31) — Basic EPS: -2.89
RNA cash_flow (annual, 2025-12-31) — Beginning Cash Position: 0.00
RNA cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 0.00
RNA cash_flow (annual, 2025-12-31) — Capital Expenditure: -1445000.00
RNA cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -879000.00
RNA balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 3672000.00
RNA balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 3672000.00
RNA balance_sheet (annual, 2025-12-31) — Capital Stock: 17000.00
RNA balance_sheet (quarterly, 2025-12-31) — Capital Stock: 17000.00
RNA balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 270000000.00
RNA balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 270000000.00
RNA balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 270000000.00
RNA balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 270000000.00
RNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 42574000.00
RNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 20131000.00
RNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -1445000.00
RNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -879000.00
RNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -41129000.00
RNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -19252000.00
RNA cash_flow (annual, 2025-12-31) — Change In Account Payable: 3728000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 3809000.00
RNA cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 10451000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 5270000.00
RNA cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -1310000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: -1310000.00
RNA cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: 0.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: 0.00
RNA cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -12017000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -1736000.00
RNA cash_flow (annual, 2025-12-31) — Change In Payable: 3728000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Payable: 3809000.00
RNA cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 14179000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 9079000.00
RNA cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -1052000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -273000.00
RNA cash_flow (annual, 2025-12-31) — Change In Receivables: 0.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Receivables: 0.00
RNA cash_flow (annual, 2025-12-31) — Change In Working Capital: -200000.00
RNA cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 5760000.00
RNA cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 0.00
RNA cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 0.00
RNA balance_sheet (annual, 2025-12-31) — Common Stock: 17000.00
RNA balance_sheet (quarterly, 2025-12-31) — Common Stock: 17000.00
RNA balance_sheet (annual, 2025-12-31) — Common Stock Equity: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 207287000.00
RNA balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 8945000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 8945000.00
RNA balance_sheet (annual, 2025-12-31) — Current Assets: 272845000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Assets: 272845000.00
RNA balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 3672000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 3672000.00
RNA balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 3672000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 3672000.00
RNA balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 21639000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 21639000.00
RNA balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 21639000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 21639000.00
RNA balance_sheet (annual, 2025-12-31) — Current Liabilities: 41801000.00
RNA balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 41801000.00
RNA cash_flow (annual, 2025-12-31) — Deferred Income Tax: -142000.00
RNA cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: 34000.00
RNA cash_flow (annual, 2025-12-31) — Deferred Tax: -142000.00
RNA cash_flow (quarterly, 2025-12-31) — Deferred Tax: 34000.00
RNA cash_flow (annual, 2025-12-31) — Depreciation: 323000.00
RNA cash_flow (quarterly, 2025-12-31) — Depreciation: 122000.00
RNA cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 323000.00
RNA cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 122000.00
RNA cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 323000.00
RNA cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 122000.00
RNA income_statement (annual, 2025-12-31) — Diluted Average Shares: 17105643.00
RNA income_statement (annual, 2025-12-31) — Diluted EPS: -2.89
RNA income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -48069000.00
RNA income_statement (annual, 2025-12-31) — EBIT: -76814000.00
RNA income_statement (quarterly, 2025-12-31) — EBIT: -48035000.00
RNA income_statement (annual, 2025-12-31) — EBITDA: -76491000.00
RNA income_statement (quarterly, 2025-12-31) — EBITDA: -47913000.00
RNA cash_flow (annual, 2025-12-31) — End Cash Position: 0.00
RNA cash_flow (quarterly, 2025-12-31) — End Cash Position: 0.00
RNA cash_flow (annual, 2025-12-31) — Financing Cash Flow: 42574000.00
RNA cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 20131000.00
RNA cash_flow (annual, 2025-12-31) — Free Cash Flow: -42574000.00
RNA cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -20131000.00
RNA cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: 140000.00
RNA income_statement (annual, 2025-12-31) — General And Administrative Expense: 41676000.00
RNA income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 30397000.00
RNA balance_sheet (annual, 2025-12-31) — Gross PPE: 8352000.00
RNA balance_sheet (quarterly, 2025-12-31) — Gross PPE: 8352000.00
RNA balance_sheet (annual, 2025-12-31) — Invested Capital: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Invested Capital: 207287000.00
RNA cash_flow (annual, 2025-12-31) — Investing Cash Flow: -1445000.00
RNA cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -879000.00
RNA balance_sheet (annual, 2025-12-31) — Leases: 0.00
RNA balance_sheet (quarterly, 2025-12-31) — Leases: 0.00
RNA balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 1771000.00
RNA balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 1771000.00
RNA income_statement (annual, 2025-12-31) — Net Income: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Net Income: -48069000.00
RNA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -48069000.00
RNA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -48069000.00
RNA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -48069000.00
RNA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -48069000.00
RNA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -49501000.00
RNA cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -29136000.00
RNA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -48069000.00
RNA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 42574000.00
RNA cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 20131000.00
RNA balance_sheet (annual, 2025-12-31) — Net PPE: 5508000.00
RNA balance_sheet (quarterly, 2025-12-31) — Net PPE: 5508000.00
RNA cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -1445000.00
RNA cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -879000.00
RNA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 207287000.00
RNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 28691000.00
RNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 28691000.00
RNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 28691000.00
RNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 28691000.00
RNA income_statement (annual, 2025-12-31) — Normalized EBITDA: -76491000.00
RNA income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -47913000.00
RNA income_statement (annual, 2025-12-31) — Normalized Income: -76684000.00
RNA income_statement (quarterly, 2025-12-31) — Normalized Income: -48069000.00
RNA cash_flow (annual, 2025-12-31) — Operating Cash Flow: -41129000.00
RNA cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -19252000.00
RNA cash_flow (annual, 2025-12-31) — Operating Gains Losses: 140000.00
RNA income_statement (annual, 2025-12-31) — Operating Income: -76814000.00
RNA income_statement (quarterly, 2025-12-31) — Operating Income: -48035000.00
RNA income_statement (annual, 2025-12-31) — Operating Revenue: 18618000.00
RNA income_statement (quarterly, 2025-12-31) — Operating Revenue: 859000.00
RNA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 17105643.00
RNA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 17105643.00
RNA balance_sheet (annual, 2025-12-31) — Other Current Assets: 1310000.00
RNA balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 1310000.00
RNA income_statement (annual, 2025-12-31) — Other Gand A: 41676000.00
RNA income_statement (quarterly, 2025-12-31) — Other Gand A: 30397000.00
RNA income_statement (annual, 2025-12-31) — Other Income Expense: -12000.00
RNA income_statement (quarterly, 2025-12-31) — Other Income Expense: 0.00
RNA cash_flow (annual, 2025-12-31) — Other Non Cash Items: 572000.00
RNA cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 276000.00
RNA balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 574000.00
RNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 574000.00
RNA income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: -12000.00
RNA income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 0.00
RNA balance_sheet (annual, 2025-12-31) — Other Properties: 6581000.00
RNA balance_sheet (quarterly, 2025-12-31) — Other Properties: 6581000.00
RNA balance_sheet (annual, 2025-12-31) — Payables: 4398000.00
RNA balance_sheet (quarterly, 2025-12-31) — Payables: 4398000.00
RNA balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 13343000.00
RNA balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 13343000.00
RNA balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 3147000.00
RNA balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 3147000.00
RNA balance_sheet (annual, 2025-12-31) — Prepaid Assets: 1535000.00
RNA balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 1535000.00
RNA income_statement (annual, 2025-12-31) — Pretax Income: -76826000.00
RNA income_statement (quarterly, 2025-12-31) — Pretax Income: -48035000.00
RNA balance_sheet (annual, 2025-12-31) — Properties: 0.00
RNA balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
RNA cash_flow (annual, 2025-12-31) — Purchase Of PPE: -1445000.00
RNA cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -879000.00
RNA income_statement (annual, 2025-12-31) — Reconciled Depreciation: 323000.00
RNA income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 122000.00
RNA income_statement (annual, 2025-12-31) — Research And Development: 53756000.00
RNA income_statement (quarterly, 2025-12-31) — Research And Development: 18497000.00
RNA income_statement (annual, 2025-12-31) — Selling General And Administration: 41676000.00
RNA income_statement (quarterly, 2025-12-31) — Selling General And Administration: 30397000.00
RNA balance_sheet (annual, 2025-12-31) — Share Issued: 17105643.00
RNA balance_sheet (quarterly, 2025-12-31) — Share Issued: 17105643.00
RNA cash_flow (annual, 2025-12-31) — Stock Based Compensation: 7679000.00
RNA cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 3552000.00
RNA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 207287000.00
RNA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 207287000.00
RNA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
RNA income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
RNA income_statement (annual, 2025-12-31) — Tax Provision: -142000.00
RNA income_statement (quarterly, 2025-12-31) — Tax Provision: 34000.00
RNA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
RNA income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
RNA balance_sheet (annual, 2025-12-31) — Total Assets: 278353000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Assets: 278353000.00
RNA balance_sheet (annual, 2025-12-31) — Total Capitalization: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 207287000.00
RNA balance_sheet (annual, 2025-12-31) — Total Debt: 3672000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Debt: 3672000.00
RNA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 207287000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 207287000.00
RNA income_statement (annual, 2025-12-31) — Total Expenses: 95432000.00
RNA income_statement (quarterly, 2025-12-31) — Total Expenses: 48894000.00
RNA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 71066000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 71066000.00
RNA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 5508000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 5508000.00
RNA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 29265000.00
RNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 29265000.00
RNA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -76814000.00
RNA income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -48035000.00
RNA balance_sheet (annual, 2025-12-31) — Working Capital: 231044000.00
RNA balance_sheet (quarterly, 2025-12-31) — Working Capital: 231044000.00
RNA income_statement (quarterly, 2026-03-31) — +Operating Expense: 36915000.00
RNA income_statement (quarterly, 2026-03-31) — +Total Revenue: 2101348.46
RNA balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 807000.00
RNA balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 15000000.00
RNA balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 221960000.00
RNA income_statement (quarterly, 2026-03-31) — Basic Average Shares: 17105643.00
RNA income_statement (quarterly, 2026-03-31) — Basic EPS: -0.97
RNA cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 0.00
RNA cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -2098000.00
RNA balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 2680000.00
RNA balance_sheet (quarterly, 2026-03-31) — Capital Stock: 16000.00
RNA balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 267849000.00
RNA balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 267849000.00
RNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 301505000.00
RNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -2098000.00
RNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -31143000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -3591000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -3051000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 1208000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -574000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -5664000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Payable: -3591000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -6642000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -1043000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Receivables: -15000000.00
RNA cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -27715000.00
RNA cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -15000000.00
RNA cash_flow (quarterly, 2026-03-31) — Changes In Cash: 268264000.00
RNA balance_sheet (quarterly, 2026-03-31) — Common Stock: 16000.00
RNA balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 234104000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 6983000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Assets: 285565000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 2680000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 2680000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 9344000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 9344000.00
RNA balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 21905000.00
RNA cash_flow (quarterly, 2026-03-31) — Depreciation: 151000.00
RNA cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 151000.00
RNA cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 151000.00
RNA income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 17105643.00
RNA income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.97
RNA income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -16633000.00
RNA income_statement (quarterly, 2026-03-31) — EBIT: -17280000.00
RNA income_statement (quarterly, 2026-03-31) — EBITDA: -17129000.00
RNA cash_flow (quarterly, 2026-03-31) — End Cash Position: 268264000.00
RNA cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 301505000.00
RNA cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -33241000.00
RNA income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 20258000.00
RNA balance_sheet (quarterly, 2026-03-31) — Gross PPE: 6380000.00
RNA balance_sheet (quarterly, 2026-03-31) — Invested Capital: 234104000.00
RNA cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -2098000.00
RNA income_statement (quarterly, 2026-03-31) — Net Income: -16633000.00
RNA income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -16633000.00
RNA income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -16633000.00
RNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -16633000.00
RNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -16633000.00
RNA cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -16633000.00
RNA income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -16633000.00
RNA cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: 301505000.00